Article info
PDFCommentary
Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?
- Correspondence to Dr Euzebiusz Jamrozik, Monash Bioethics Centre, Monash University, Clayton, VIC 3800, Australia; zeb.jamrozik{at}monash.edu
Citation
Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?
Publication history
- Received October 18, 2020
- Accepted October 19, 2020
- First published November 5, 2020.
Online issue publication
November 27, 2020
Article Versions
- Previous version (5 November 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Other content recommended for you
- Payment in challenge studies: ethics, attitudes and a new payment for risk model
- Compensating for research risk: permissible but not obligatory
- Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy
- Commentary on 'Payment in challenge studies: ethics, attitudes and a new payment for risk model'
- Fair go: pay research participants properly or not at all
- On measuring attitudes about payment for research
- Uncertainty, error and informed consent to challenge trials of COVID-19 vaccines: response to Steel et al
- Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia
- Do coronavirus vaccine challenge trials have a distinctive generalisability problem?
- COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement